|
|
Keyword Manufacturing Search Result
FDA Approves the First Test to Identify Risk of Opioid Addiction
Can a test determine if you’re at risk for opioid addiction? The U.S. Food and Drug Administration (FDA) thinks so. That’s why the agency approved the use of the AvertD test on Tuesday, a first-of
Website link :https://adquash.com/news_q.php?str=FDA-Approves-the-First-Test-to-Identify-Risk-of-Opioid-Addiction
The Musk factor driving the Vodafone Idea stock
Ltd’s stock rose to a 52-week high on New Year’s Day to 18.42, amid news reports claiming that the government could sell its 33% stake in Vodafone Idea to tech-billionaire Elon Musk and his satell
Website link :https://adquash.com/news_q.php?str=The-Musk-factor-driving-the-Vodafone-Idea-stock
Japan startup develops ‘Gundam’-like robot with $3-million price tag
YOKOHAMA, Japan – Tokyo-based start-up Tsubame Industries has developed a 4.5-meter-tall (14.8-feet), four-wheeled robot that looks like “Mobile Suit Gundam” from the wildly popular Japanese ani
Website link :https://adquash.com/news_q.php?str=Japan_startup_develops_‘Gundam’-like_robot_with_$3-million_price_tag_69
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical’s Mezagitamab?
Mezagitamab is a monoclonal antibody commercialized by Takeda Pharmaceutical, with a leading Phase II program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). According to Glo
Website link :https://adquash.com/news_q.php?str=Risk_adjusted_net_present_value:_What_is_the_current_valuation_of_Takeda_Pharmaceutical’s_Mezagitamab_111
Intel will build $25 billion chip factory in Israel’s ‘largest investment ever’
The Israeli government and confirmed plans to build a $25 billion chipmaking factory in the south of the country, an investment Prime Minister Benjamin Netanyahu has described as the biggest in Israel
Website link :https://adquash.com/news_q.php?str=Intel-will-build-25-billion-chip-factory-in-Israels-largest-investment-ever
Risk adjusted net present value: What is the current valuation of Takeda Pharmaceutical’s Modakafusp alfa?
Modakafusp alfa is a fusion protein commercialized by Takeda Pharmaceutical, with a leading Phase II program in Relapsed Multiple Myeloma. According to Globaldata, it is involved in 2 clinical trials,
Website link :https://adquash.com/news_q.php?str=Risk_adjusted_net_present_value:_What_is_the_current_valuation_of_Takeda_Pharmaceutical’s_Modakafusp_alfa_110
